TIME recognizes HeartGuide™, the first wearable blood pressure monitor, as one of the groundbreaking inventions that are changing the way we live, work, play and think about what’s possible LAKE FOREST, Ill., Nov. 26, 2019 /PRNewswire/ — OMRON Healthcare, Inc., the global leader in personal heart health and wellness technology, is recognized in […]
Other News
InspireMD Reports Updated Positive CGuard™ EPS Data Presented at VEITH 2019
CGuard™ EPS clinical data featured as a prominent discussion point in multiple key presentations Data from investigator-initiated multicenter, 729-patient IRONGUARD 2 study suggests that the use of CGuard™ EPS in routine clinical practice is associated with no major periprocedural, 30-day or one-year neurological complications TEL AVIV, Israel, Nov. 26, 2019 […]
BioSig Technologies Signs Three New Licensing Agreements with Mayo Clinic
Westport, CT, Nov. 26, 2019 (GLOBE NEWSWIRE) — ·New areas of collaboration identified between Mayo Clinic and BioSig ·Focus on previously untapped arrhythmia treatments ·Additional development areas covering novel therapies for autonomic nervous system disease BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a […]
Neovasc Reducer™ Featured In FOCUS Magazine
VANCOUVER, CA, and BERLIN, DE, Nov. 26, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that […]
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca
Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per year Drug developers currently lack effective humanized models for preclinical testing of targeted drug candidates in heart failure with preserved ejection fraction The collaboration aims to provide a unique solution for […]
Mesoblast Financial Results for the Quarter Ended September 30, 2019
Continued Increase in Revenues and Strong Balance Sheet MELBOURNE, Australia and NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported operational highlights and financial results for the first quarter ended September 30, 2019. Mesoblast Chief Executive Dr Silviu Itescu stated: “The Company’s financial results for […]
Resverlogix Announces Warrant Exercise Incentive Program
CALGARY, Alberta, Nov. 25, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) announces a warrant exercise incentive program (“Incentive Program”) designed to encourage the early exercise of 15,593,428 warrants to purchase common shares of the Company. The Incentive Program does not apply to warrants held by […]
Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia
On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020 LAVAL, Québec, Nov. 26, 2019 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its […]
Itamar™ Medical Reports Record Third Quarter 2019 Revenues
– Third Quarter Revenues Increase 33% to $8.1 Million – – WatchPAT™ Revenues Increase 32% in the Third Quarter to $7.6 Million – – Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT – CAESAREA, Israel, Nov. 26, 2019 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: […]
OTITOPIC™ New Clinical Trial Results Continue to Demonstrate Inhibition of Platelet Aggregation in Two Minutes With Dry Powder Inhalation of Aspirin Formulation for High Risk Patients to Treat Suspected Acute Myocardial Infarction (MI)
LOS ANGELES–(BUSINESS WIRE)–OTITOPIC – A clinical-stage dry powder inhalation of aspirin pharmaceutical company pioneering the development of antithrombotic treatments for use at the time of suspected acute myocardial infarction (MI), today announced the successful conclusion based on PD results of a clinical trial for its lead drug: Dry Powder Inhalation […]



